GAMMA SECRETASE MODULATORS
In its many embodiments, the present invention provides novel heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.
1 - 15 . (canceled)
16 . A compound selected from the group consisting of: compounds P2, Q3, R2, S3, T2, U2, V8, W6, X2, X3, Y2, Z2, AA2, AA3, AB2, AC12, AD7, AE4, AG2, AH7, AI2, AJ12, 201-214, 216-266, 268-424, 437-465, and 468-553, or a pharmaceutically acceptable salt thereof.
17 . A compound selected from the group consisting of: compounds P2, Q3, R2, S3, T2, U2, V8, W6, X2, X3, Y2, Z2, AA2, AA3, AB2, AC12, AD7, AE4, AG2, AH7, 201-214, 216-266, 268-424, and 437-446.
18 . A pharmaceutically acceptable salt of a compound of claim 16 .
19 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 16 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
20 . A method of modulating gamma-secretase comprising administering an effective amount of one or more compounds of claim 16 or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
21 . A method of inhibiting the deposition of amyloid protein in, on or around neurological tissue, comprising administering an effective amount of one or more compounds of claim 16 or a pharmaceutically acceptable salt thereof to a patient in need of treatment.
22 . A method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 16 or a pharmaceutically acceptable salt thereof to a patient in need of treatment.